                         SEQUENCE LISTING

<110>  DANA-FARBER CANCER INSTITUTE, INC.
 
<120>  IN VIVO METHODS FOR IDENTIFYING CANCER-ASSOCIATED IMMUNOTHERAPY 
       TARGETS

<130>  DFS-147.25

<140>  PCT/US2015/067308
<141>  2015-12-22

<150>  62/095,271
<151>  2014-12-22

<160>  5     

<170>  PatentIn version 3.5

<210>  1
<211>  20
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  /note="Description of Artificial Sequence: Synthetic sgRNA 
       targeting sequence"

<400>  1
tatagagctg aaaaaccgca                                                   20


<210>  2
<211>  20
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  /note="Description of Artificial Sequence: Synthetic sgRNA 
       targeting sequence"

<400>  2
ccacattacg gacgatgcaa                                                   20


<210>  3
<211>  20
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  /note="Description of Artificial Sequence: Synthetic sgRNA 
       targeting sequence"

<400>  3
tcttacgagg aggagaaagg                                                   20


<210>  4
<211>  20
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  /note="Description of Artificial Sequence: Synthetic sgRNA 
       targeting sequence"

<400>  4
gcaagtgtag tttcccacca                                                   20


<210>  5
<211>  20
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  /note="Description of Artificial Sequence: Synthetic sgRNA 
       targeting sequence"

<400>  5
aaaaagtccg cgattacgtc                                                   20